» Authors » Yong S Chang

Yong S Chang

Explore the profile of Yong S Chang including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 845
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Duran J, White L, Dunn P, Chang Y, Knauer A
Cureus . 2024 Sep; 16(9):e68562. PMID: 39238922
This case report describes a patient who presented with concern for a closed-loop small bowel obstruction (SBO). During exploratory laparotomy, an area of ischemic bowel due to closed loop obstruction...
2.
Guerlavais V, Sawyer T, Carvajal L, Chang Y, Graves B, Ren J, et al.
J Med Chem . 2023 Jul; 66(14):9401-9417. PMID: 37439511
We report the discovery of sulanemadlin (ALRN-6924), the first cell-permeating, stabilized α-helical peptide to enter clinical trials. ALRN-6924 is a "stapled peptide" that mimics the N-terminal domain of the p53...
3.
Chang Y, Li S, Pertinez H, Betoudji F, Lee J, Rannard S, et al.
Antimicrob Agents Chemother . 2023 Jun; 67(7):e0048123. PMID: 37338374
Administration of tuberculosis preventive therapy (TPT) to individuals with latent tuberculosis infection is an important facet of global tuberculosis control. The use of long-acting injectable (LAI) drug formulations may simplify...
4.
Chang Y, Li S, Pertinez H, Betoudji F, Lee J, Rannard S, et al.
bioRxiv . 2023 Apr; PMID: 37090528
Administration of tuberculosis preventive therapy (TPT) to individuals with latent tuberculosis infection is an important facet of global tuberculosis control. The use of long-acting injectable (LAI) drug formulations may simplify...
5.
Green S, Davis S, Damerow S, Engelhart C, Mathieson M, Baragana B, et al.
Nat Commun . 2022 Oct; 13(1):5992. PMID: 36220877
Tuberculosis is a major global cause of both mortality and financial burden mainly in low and middle-income countries. Given the significant and ongoing rise of drug-resistant strains of Mycobacterium tuberculosis...
6.
Bigelow K, Tasneen R, Chang Y, Dooley K, Nuermberger E
Antimicrob Agents Chemother . 2020 Jul; 64(10). PMID: 32690647
The novel regimen of bedaquiline, pretomanid, and linezolid (BPaL) is highly effective against drug-resistant tuberculosis, but linezolid toxicities are frequent. We hypothesized that, for a similar total weekly cumulative dose,...
7.
Tucker E, Guglieri-Lopez B, Ordonez A, Ritchie B, Klunk M, Sharma R, et al.
Sci Transl Med . 2018 Dec; 10(470). PMID: 30518610
Tuberculous meningitis (TBM) is a devastating form of tuberculosis (TB), and key TB antimicrobials, including rifampin, have restricted brain penetration. A lack of reliable data on intralesional drug biodistribution in...
8.
Ordonez A, Pokkali S, Kim S, Carr B, Klunk M, Tong L, et al.
PLoS One . 2018 May; 13(5):e0197474. PMID: 29758082
Matrix metalloproteinase (MMP)-9 is a zinc-dependent protease associated with early immune responses to Mycobacterium tuberculosis infection, macrophage recruitment and granuloma formation. We evaluated whether adjunctive inhibition of MMP-9 could improve...
9.
Zhang Z, Ordonez A, Smith-Jones P, Wang H, Gogarty K, Daryaee F, et al.
PLoS One . 2017 Feb; 12(2):e0170871. PMID: 28151985
5-[18F]F-pyrazinamide (5-[18F]F-PZA), a radiotracer analog of the first-line tuberculosis drug pyrazinamide (PZA), was employed to determine the biodistribution of PZA using PET imaging and ex vivo analysis. 5-[18F]F-PZA was synthesized...
10.
Ashbaugh A, Jiang X, Zheng J, Tsai A, Kim W, Thompson J, et al.
Proc Natl Acad Sci U S A . 2016 Oct; 113(45):E6919-E6928. PMID: 27791154
Bacterial biofilm formation is a major complication of implantable medical devices that results in therapeutically challenging chronic infections, especially in cases involving antibiotic-resistant bacteria. As an approach to prevent these...